Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Combination of antigens from multiple viral species
Reexamination Certificate
2007-05-15
2007-05-15
Parkin, Jeffrey S. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Combination of antigens from multiple viral species
C424S218100
Reexamination Certificate
active
10626315
ABSTRACT:
The present invention provides vaccine compositions of attenuated dengue virus. More specifically, the attenuated virus is produced by serial passage in PDK cells. The invention also provides methods for stimulating the immune system of an individual to induce protection against all four dengue virus serotypes by administration of attenuated dengue-1, dengue-2, dengue-3, and dengue-4 virus.
REFERENCES:
patent: 5723130 (1998-03-01), Hancock et al.
patent: 6638514 (2003-10-01), Eckels et al.
Trent, D. W., et al., “Genetic variation and microevolution of dengue 2 virus in Southeast Asia.”, VIROLOGY, (Oct. 1989) 172(2): 523-535.
Rico Hesse, R., et al., “Molecular evolution of dengue type 2 virus in Thailand.”, American Journal of Tropical Medicine and Hygiene, (Jan. 1998) 58(1):96-101.
Holmes, E. C. and S. S. Burch, “The causes and consequences of genetic variation in dengue virus.”, Trends in Microbiology, (Feb. 2000) 8(2):74-77.
Harrison, V. R., et al., “Virulence and immunogenicity of a temperature sensitive dengue 2 virus in lower primates.”, Infection and Immunity, (Oct. 1977) 18(1):151-156.
Kinney, R. M., et al., “Construction of Infectious cDNA clones for dengue 2 virus:strain 16681 and its attenuated vaccine derivative, strain PDK 53.”, VIROLOGY, (Apr. 14, 1997) 230(2):300-308.
Vaughn, D. W., et al., “Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers.”, VACCINE, (1996) 14(4):329-336.
Edelman, R., et al.,“A live attenuated dengue-1 vaccine candidate (45AZ5) passaged in primary dog kidney cell culture is attenuated adn immunogenic for humans”, JID, (1994) 170:1448-1455.
Angsubhakorn, S., et al., “Dengue-3 (16562) PCMK 33 vaccine: neurovirulence, viremia, and immune responses inMacaca facisularis”, Southeast Asian J. Trop. Med. Public Health, (Sep. 1994) 25(3):554-559.
Hoke, C. H., et al., “Preparation of an attenuated dengue 4 (34750 Carib) virus vaccine. II. Safety and immunogenicity in humans”, Am. J. Trop. Med. Hyg., (1990), 43(2):219-226.
Botstein and Shortle, 1985, “Strategies and applications of in vitro mutagenesis”, Science, vol. 229, No. 4719, pp. 1193-1201.
Clarke and Casals, 1958, “Techniques for hemagglutination and hemagglutination-inhibition with arthropod-borne viruses”, Am. J. Trop. Med. Hyg., 7, 561-573.
Halstead et al., 1984, “Selection of attenuated Dengue 4 viruses by serial passage in primary kidney cells,” Am J. Trop. Med. Hyg, 33(4), pp. 654-665.
Halstead et al., 1984, “Selection of attenuated Dengue 4 viruses by seral passage in primary kidney cells,” Am J. Trop. Med. Hyg, 33(4), pp. 666-671.
Halstead et al., 1984, “Selection of attenuated Dengue 4 viruses by serial passage in primary kidney cells,” Am J. Trop. Med. Hyg, 33(4), pp. 672-678.
Halstead et al., 1984, “Selection of attenuated Dengue 4 viruses by serial passage in primary kidney cells,” Am J. Trop. Med. Hyg, 33(4), pp. 679-683.
Hayflick, 1988, “History of cell substrates used for human biologicals”, Symposium on Continuous Cell Lines as Substrates for Biologicals, Arlington, Virginia, USA, pp. 11-26.
Hoke et al., 1990, “Preparation of an attenuated Dengue 4 virus vaccine”, Am J. Top. Med. Hyg., 43(2), pp. 219-226.
Marchette, 1990, “Preparation of an attenuated Dengue 4 virus vaccine”, Am J. Top. Med. Hyg., 43(2), pp. 212-218.
Mizrahi, ed., Viral Vaccines, “WHO Attitude to Viral Vaccines”, Wiley-Liss, New York (1990), pp. 39-60.
Putnak et al, 1996, “Development of a purified, inactivated, Dengue-2 virus vaccine prototype in vero cells: immunogenecity and protection in mice nad Rhesus monkeys,” J. Infectious Dis., 174, pp. 1176-1184.
Russell, et al., “A plaque reduction test for dengue virus neutralizing antibodies”, J. Immunology, vol. 99, No. 2, 1967, pp. 285-290.
Scott, 1983, “Dengue 2 vaccine: Dose response in volunteers in relation to yellow fever immune status,” J. Infectious Diseases, vol., 148, No 6, pp. 1055-1060.
Sukhavachana et al., 1966, “Tissue culture techniques for the study of dengue viruses”, Abreges des Communications, Bull. WHO 35, pp. 65-66.
Zoller and Smith, 1984, Laboratory Methods, “Oligonucleotide-directed mutagenesis: a simple method using two oligonucleotide primers and a single-stranded DNA template”, DNA, vol. 3, No. 6, pp. 479-488.
Bhamarapravati, 1987, “Immunization with a live attenuated dengue-2-virus candidate vaccine: clinical, immunological and biological responses in adult volunteers”, Bull. WHO, 65(2), pp. 189-195.
Conrad et al., “Infection with Nippostrongylus Brasiliensis or injection of anti-IgD antibodies markedly enhances Fc-receptor-mediated interleukin 4 production by non-B, non-T cells”, 1990, J. Exp. Med., vol. 171, pp. 1497-1508.
Dharakul, et al., “Dengue virus-specific memory T cell responses in human volunteers receiving a live attenuated dengue virus Type 2 candidate vaccine”, 1994 J. Infect. Dis., vol. 170, pp. 27-33.
Edelman et al., “A live attenuated Dengue-1 vaccine candidate passaged in primary dog kidney cell culture is attenuated and immunogenic or humans”, 1994, Am. J. Trop. Med. Hyg., 170, pp. 1448-1455.
Halstead, 1978, “Studies on the attenuation of Dengue 4”, Asian J. Infectious Dis., vol. 2, pp. 112-117.
Halstead, 1970, “Long ‘cure’ improves results of pig heterograft heart valves,” JAMA, vol. 211, No. 6. pp. 911-916.
Johnson and Roehrig, “New mouse model for Dengue virus vaccien testing”, J. Virology, Jan. 1999, vol. 73, No. 1, pp. 783-786.
Kontny et al., “Gamma interferon augments Fcy receptor-mediated Dengue virus infection of human monocytic cells”, J. Virology. Nov. 1988, vol. 62, No. 11, pp. 3928-3933.
Kurane et al., “Dengue virus-specific human T cell clones”,J. Exp. Med., vol. 170, 1989, pp. 763-775.
Kurane et al., “Activation of T lymphocytes in dengue virus infections”, J. Clin. Invest., vol. 88, 1991, pp. 1473-1480.
Kurane et al., “T cell activation in vivo by Dengue virus infection”, J. Clin. Lab. Immunol., 1995, vol. 46, pp. 35-40.
Peters, “Actions of cytokines on the immune response and viral interactions: an overview”, Hepatology, vol. 23, 1996, pp. 909-916.
Sittisombut et al., “Lack of augmenting effect of interferon-y on Dengue virus multiplication in human peripheral blood monocytes”, J. Medical Virology 45:43-49, 1995.
Sabin, 1959, “Dengue”, Viral and Rickettsial Infections of Man, Philadelphia: JB Lippincott Company, pp. 361-373.
Simmons et al., “Experimental Studies of Dengue”, 1931, Manila BUreau of Printing, pp. 1-489.
Wisseman and Sweet, “Immunological studies with Group B arthropod-borne viruses”, Am J. Trop. Med. Hyg., vol. 11, pp. 570-575 (1962).
Yuill et al., “Dengue-virus recovery by direct and delayed plaques in LLC-MK2 cells”, Am. J. Trop. Med. Hyg., vol. 17, 1968, pp. 441-448.
Edelman, et al., “A Live Attenuated Dengue-1 Vaccine Candidate (45AZ5) Passaged in Primary Dog Kidney Cell Culture SIs Attenuated and Immunogenic for Humans”, J. Infectious Diseases, 1994:170:1448-1455 (Dec.).
Angsubharkorn et al., “Dengue-3 (16562) PGMK 33 Vaccine: Neurovirulence, Viremia and Immune Responses inMacaca fascicularis”, Southeast Asian J. Trop. Med. Public Health, vol. 25, No. 3, Sep. 1994.
(XP-002150293) Sun et al., Program Abstracts from the First Annual Conference on Vaccine Research, May 30-Jun. 1, 1998, “Phase I Study of Two Doses of Monovalent Live-Attenuated Dengue Virus Vaccines” (2 pages).
Vaughn, et al., “Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers”, Vaccine, vol. 14, No. 4, pp
Dubois Doria R.
Eckels Kenneth H.
Hoke Charles H.
Innis Bruce L.
Kanesa-Thasan Niranjan
Arwine Elizabeth
Parkin Jeffrey S.
United States of America as represented by the Secretary of the
LandOfFree
Multivalent dengue virus vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Multivalent dengue virus vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Multivalent dengue virus vaccine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3737469